Cargando…

The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity

Doxorubicin (DOX) is widely used as a chemotherapeutic agent for liver cancer. However, its clinical applications are greatly restricted by its nonselective cytotoxicity. A novel magnetic prodrug, Fe(3)O(4)@DOX, was designed, synthesized and characterized, and Fe(3)O(4) and DOX were connected by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Li, Liang, Lv, Yang, Zou, Hao, Wei, Yanping, Nie, Fei, Duan, Wanli, Sedike, Maidinamu, Xiao, Liang, Wang, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055880/
https://www.ncbi.nlm.nih.gov/pubmed/35520056
http://dx.doi.org/10.1039/d0ra01729a
_version_ 1784697512152530944
author Li, Jun
Li, Liang
Lv, Yang
Zou, Hao
Wei, Yanping
Nie, Fei
Duan, Wanli
Sedike, Maidinamu
Xiao, Liang
Wang, Mei
author_facet Li, Jun
Li, Liang
Lv, Yang
Zou, Hao
Wei, Yanping
Nie, Fei
Duan, Wanli
Sedike, Maidinamu
Xiao, Liang
Wang, Mei
author_sort Li, Jun
collection PubMed
description Doxorubicin (DOX) is widely used as a chemotherapeutic agent for liver cancer. However, its clinical applications are greatly restricted by its nonselective cytotoxicity. A novel magnetic prodrug, Fe(3)O(4)@DOX, was designed, synthesized and characterized, and Fe(3)O(4) and DOX were connected by the peptide CGGAAN. The magnetic prodrug Fe(3)O(4)@DOX was successfully synthesized with average sizes of 95 nm and 322.5 nm by TEM (transmission electron microscopy) and Malvern Zetasizer instrument respectively. The maximum emission wavelength shifted from 594 nm for free DOX to 615 nm for conjugated DOX in the synthesized Fe(3)O(4)@DOX. Both free DOX and Fe(3)O(4)@DOX show strong cytotoxicity to legumain overexpressing PLC through apoptosis. Similarly, Fe(3)O(4)@DOX and DOX equally reduced tumor volume and induced cell apoptosis in tumor tissues, while the former significantly maintained body weight and extended the life of nude mice, therefore serving as a promising nanocarrier for liver cancer treatment.
format Online
Article
Text
id pubmed-9055880
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90558802022-05-04 The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity Li, Jun Li, Liang Lv, Yang Zou, Hao Wei, Yanping Nie, Fei Duan, Wanli Sedike, Maidinamu Xiao, Liang Wang, Mei RSC Adv Chemistry Doxorubicin (DOX) is widely used as a chemotherapeutic agent for liver cancer. However, its clinical applications are greatly restricted by its nonselective cytotoxicity. A novel magnetic prodrug, Fe(3)O(4)@DOX, was designed, synthesized and characterized, and Fe(3)O(4) and DOX were connected by the peptide CGGAAN. The magnetic prodrug Fe(3)O(4)@DOX was successfully synthesized with average sizes of 95 nm and 322.5 nm by TEM (transmission electron microscopy) and Malvern Zetasizer instrument respectively. The maximum emission wavelength shifted from 594 nm for free DOX to 615 nm for conjugated DOX in the synthesized Fe(3)O(4)@DOX. Both free DOX and Fe(3)O(4)@DOX show strong cytotoxicity to legumain overexpressing PLC through apoptosis. Similarly, Fe(3)O(4)@DOX and DOX equally reduced tumor volume and induced cell apoptosis in tumor tissues, while the former significantly maintained body weight and extended the life of nude mice, therefore serving as a promising nanocarrier for liver cancer treatment. The Royal Society of Chemistry 2020-08-05 /pmc/articles/PMC9055880/ /pubmed/35520056 http://dx.doi.org/10.1039/d0ra01729a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Li, Jun
Li, Liang
Lv, Yang
Zou, Hao
Wei, Yanping
Nie, Fei
Duan, Wanli
Sedike, Maidinamu
Xiao, Liang
Wang, Mei
The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
title The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
title_full The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
title_fullStr The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
title_full_unstemmed The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
title_short The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
title_sort construction of the novel magnetic prodrug fe(3)o(4)@dox and its antagonistic effects on hepatocarcinoma with low toxicity
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055880/
https://www.ncbi.nlm.nih.gov/pubmed/35520056
http://dx.doi.org/10.1039/d0ra01729a
work_keys_str_mv AT lijun theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT liliang theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT lvyang theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT zouhao theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT weiyanping theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT niefei theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT duanwanli theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT sedikemaidinamu theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT xiaoliang theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT wangmei theconstructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT lijun constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT liliang constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT lvyang constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT zouhao constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT weiyanping constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT niefei constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT duanwanli constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT sedikemaidinamu constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT xiaoliang constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity
AT wangmei constructionofthenovelmagneticprodrugfe3o4doxanditsantagonisticeffectsonhepatocarcinomawithlowtoxicity